Orantinib

Drug Profile

Orantinib

Alternative Names: SU 006668; SU 6668; TSU-68

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Pfizer; Taiho Pharmaceutical
  • Class Antineoplastics; Indoles; Propionic acids; Pyrroles; Small molecules
  • Mechanism of Action Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Gastric cancer; Hepatocellular carcinoma; Non-small cell lung cancer
  • Discontinued Solid tumours

Most Recent Events

  • 31 Jul 2014 Taiho Pharmaceutical terminates the phase III ORIENTAL trial for Hepatocellular carcinoma (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 18 Feb 2014 Taiho Pharmaceutical completes enrolment in the phase III ORIENTAL trial for Hepatocellular carcinoma (unresectable disease; combination therapy) in Japan, South Korea & Taiwan (NCT01465464)
  • 13 Apr 2012 Orantinib is still in phase I trials for Non-small cell lung cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top